JP2011172579A5 - - Google Patents

Download PDF

Info

Publication number
JP2011172579A5
JP2011172579A5 JP2011083817A JP2011083817A JP2011172579A5 JP 2011172579 A5 JP2011172579 A5 JP 2011172579A5 JP 2011083817 A JP2011083817 A JP 2011083817A JP 2011083817 A JP2011083817 A JP 2011083817A JP 2011172579 A5 JP2011172579 A5 JP 2011172579A5
Authority
JP
Japan
Prior art keywords
present
dtdt
seq
consecutive
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011083817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011172579A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011172579A publication Critical patent/JP2011172579A/ja
Publication of JP2011172579A5 publication Critical patent/JP2011172579A5/ja
Pending legal-status Critical Current

Links

JP2011083817A 2004-01-30 2011-04-05 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法 Pending JP2011172579A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54068704P 2004-01-30 2004-01-30
US60/540,687 2004-01-30
US64152205P 2005-01-04 2005-01-04
US60/641,522 2005-01-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006550491A Division JP4755113B2 (ja) 2004-01-30 2005-01-27 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2011172579A JP2011172579A (ja) 2011-09-08
JP2011172579A5 true JP2011172579A5 (enExample) 2012-07-05

Family

ID=34830511

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006550491A Expired - Fee Related JP4755113B2 (ja) 2004-01-30 2005-01-27 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法
JP2011083817A Pending JP2011172579A (ja) 2004-01-30 2011-04-05 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006550491A Expired - Fee Related JP4755113B2 (ja) 2004-01-30 2005-01-27 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法

Country Status (6)

Country Link
US (3) US20050197310A1 (enExample)
EP (2) EP1758998B1 (enExample)
JP (2) JP4755113B2 (enExample)
AT (1) ATE491715T1 (enExample)
DE (1) DE602005025347D1 (enExample)
WO (1) WO2005072057A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE491715T1 (de) * 2004-01-30 2011-01-15 Quark Pharmaceuticals Inc Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
US20100266574A1 (en) * 2005-06-10 2010-10-21 Orna Mor Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
US8299040B2 (en) * 2006-10-18 2012-10-30 Board Of Regents, The University Of Texas System Methods for treating cancer targeting transglutaminase
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US20100273854A1 (en) * 2007-06-15 2010-10-28 Hagar Kalinski Compositions and methods for inhibiting nadph oxidase expression
WO2009132351A2 (en) * 2008-04-25 2009-10-29 University Of Medicine And Dentistry Of New Jersey Anti-sense microrna expression vectors
WO2012108841A1 (en) * 2011-02-09 2012-08-16 Singapore Health Services Pte. Ltd. Transglutaminase-2 inhibitors and uses thereof
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
WO2013142514A1 (en) * 2012-03-19 2013-09-26 Isis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
KR101881662B1 (ko) * 2016-05-12 2018-07-26 강원대학교산학협력단 당뇨성 합병증 예방 및 치료용 약제학적 조성물 및 당뇨성 합병증 예방 또는 치료제 스크리닝 방법
US10155948B2 (en) 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
IT201800009133A1 (it) * 2018-10-03 2020-04-03 Università Cattolica del Sacro Cuore Identificazione di biomarcatori molecolari predittivi di risposta al trattamento radiochemoterapico nel carcinoma della cervice
IL316071A (en) * 2022-04-14 2024-12-01 Aro Biotherapeutics Company Fn3 domain-sirna conjugates with enzyme replacement therapy

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US5021440A (en) 1989-07-31 1991-06-04 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US4968713A (en) 1989-07-31 1990-11-06 Merck & Co., Inc. Certain imidazole compounds as transglutaminase inhibitors
US5098707A (en) 1989-07-31 1992-03-24 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
AU6620596A (en) * 1996-07-25 1998-02-20 Victoria University Of Manchester, The Use of transglutaminase modulators to promote wound healing
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6365577B1 (en) 1998-10-26 2002-04-02 Avi Biopharma, Inc. p53 antisense agent and method
US6773916B1 (en) * 1999-01-05 2004-08-10 The Flinders University Of South Australia Agents and methods for treatment and diagnosis of ocular disorders
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
AU2002305236A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
WO2002085308A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20040019001A1 (en) 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
JP2005517423A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＴＧＦ−ベータおよびＴＧＦ−ベータレセプター遺伝子の発現のＲＮＡ干渉媒介性阻害
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
BRPI0313202A8 (pt) 2002-08-05 2016-08-16 Atugen Ag Formas adicionais para interferir com as moléculas de rna
EP1563094A4 (en) * 2002-10-29 2007-04-25 Rigel Pharmaceuticals Inc MODULATORS OF ANGIOGENESIS AND TUMORIGENESIS
WO2004113496A2 (en) * 2003-06-20 2004-12-29 Isis Pharmaceuticals, Inc. Double stranded compositions comprising a 3’-endo modified strand for use in gene modulation
ATE491715T1 (de) 2004-01-30 2011-01-15 Quark Pharmaceuticals Inc Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten

Similar Documents

Publication Publication Date Title
JP2011172579A5 (enExample)
JP2013539454A5 (enExample)
JP2011155981A5 (enExample)
JP2012505657A5 (enExample)
EP2647644A4 (en) 2'-O-MODIFIED RNA
WO2013006795A3 (en) Antiviral compositions and methods of their use
JP2011168603A5 (enExample)
JP2010523596A5 (enExample)
IL264288B (en) Methods and compositions for modulating apolipoprotein(a) expression
IL206462A0 (en) Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
CY1115253T1 (el) Κρυσταλλικες μορφες ενος παραγωγου 2-θειαζολυλο-4-κινολινυλ-οξυ-ομαδας, ενος ισχυρου αναστολεα του ηcv
JP2011136981A5 (enExample)
JP2009541403A5 (enExample)
WO2011139699A3 (en) 5' modified nucleosides and oligomeric compounds prepared therefrom
EP2424987A4 (en) HEMOGLOBIN ANTISENSE OLIGONUCLEOTIDES
JP2010088434A5 (enExample)
JP2013512915A5 (enExample)
JP2015501155A5 (enExample)
MY160722A (en) Preparing high order hydridosilane compounds
JP2014521310A5 (enExample)
JP2013504665A5 (enExample)
JP2012105193A5 (enExample)
JP2013503110A5 (enExample)
WO2011116152A3 (en) Delivery of agents using interfering nanoparticles
JP2015128433A5 (enExample)